Psychoactive drug
A new clinical trial found a 57 percent remission in depression symptoms over 12 weeks, after just a single intravenous dose the drug.
A growing new industry around psychedelic therapy is utilizing biopiracy tactics to steal indigenous knowledge of new drugs.
With the growing popularity of psychedelics, therapists are popping up to guide patients on their inner trips—they just can’t help score the drugs. (Yet.)
This could be the future treatment of mood disorders like depression.
For the millions of people suffering from depression, ketamine could be a brilliant fix—if the trippy side-effects were gone.
The experience, Christian Angermayer said, “was the single most meaningful thing I’ve done in my whole life.”
Shroom legalization is at hand in Oregon, and the ponytailed, vegan, soap-selling financier behind it all says your state could be next.